PYOTT DAVID E I — SEC insider filings
SEC reporting owner CIK 1051578. 28 insider filings on record with FilingPulse; latest filed 2026-11-12.
Transaction summary — filings shown
Covers all 28 filings on record, filed 2020-09-01 to 2026-11-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 1 filing — 12,800 shares, $1,001,715 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 9 legs across 3 filings — 43,720 shares, $10,531,773 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 43.
- Largest priced transaction: sale of 17,560 shares @ $220.00 ($3,863,200) in ALNYLAM PHARMACEUTICALS, INC., filed 2024-06-26.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Director | 12 | — | 9 legs · 43,720 sh · $10,531,773 | 23 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | Director | 5 | 2 legs · 12,800 sh · $1,001,715 | — | 4 |
| Tarsus Pharmaceuticals, Inc. (TARS) | Director | 4 | — | — | 9 |
| PLIANT THERAPEUTICS, INC. (PLRX) | Director | 7 | — | — | 7 |
Insider filings — PYOTT DAVID E I
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-12 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 3,780 @ $71.99 · Option exercise (M): 3,780 (derivative) @ $0 | EDGAR |
| 2026-09-17 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 201 · Option exercise (M): 201 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 3,837 (derivative) @ $0 · Grant/award (A): 2,417 (derivative) @ $0 · Grant/award (A): 806 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 3,830 @ $0 · Sale (S): 921 @ $297.71 · Sale (S): 1,175 @ $298.91 · Sale (S): 1,222 @ $299.87 · Sale (S): 495 @ $300.72 · Sale (S): 17 @ $302.65 · +1 more | EDGAR |
| 2026-05-22 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 671 @ $0 · Grant/award (A): 1,441 (derivative) @ $0 | EDGAR |
| 2026-04-28 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 1,383 · Option exercise (M): 1,383 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 5,893 (derivative) @ $0 · Grant/award (A): 3,729 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | PLIANT THERAPEUTICS, INC. (PLRX) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-05-12 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 775 @ $0 · Grant/award (A): 1,558 (derivative) @ $0 | EDGAR |
| 2025-03-25 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 7,440 @ $88.95 · Sale (S): 7,440 @ $299 · Option exercise (M): 7,440 (derivative) @ $0 | EDGAR |
| 2024-06-26 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 17,560 @ $88.95 · Option exercise (M): 7,420 @ $70.20 · Option exercise (M): 7,470 @ $71.99 · Sale (S): 17,560 @ $220 · Sale (S): 7,420 @ $221 · Sale (S): 7,470 @ $222 · +3 more | EDGAR |
| 2024-06-17 | 4 | PLIANT THERAPEUTICS, INC. (PLRX) | Grant/award (A): 26,764 (derivative) @ $0 | EDGAR |
| 2024-05-23 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 4,720 @ $0 | EDGAR |
| 2024-05-20 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 5,228 (derivative) @ $0 | EDGAR |
| 2023-06-08 | 4 | PLIANT THERAPEUTICS, INC. (PLRX) | Grant/award (A): 14,000 (derivative) @ $0 | EDGAR |
| 2023-05-24 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 4,190 @ $0 | EDGAR |
| 2023-05-19 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 3,454 (derivative) @ $0 | EDGAR |
| 2023-02-27 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 136 @ $0 · Option exercise (M): 136 (derivative) @ $0 | EDGAR |
| 2022-06-21 | 4 | PLIANT THERAPEUTICS, INC. (PLRX) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2022-05-26 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 4,980 @ $0 | EDGAR |
| 2022-05-20 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 5,153 (derivative) @ $0 | EDGAR |
| 2022-02-25 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 136 (derivative) @ $0 | EDGAR |
| 2021-07-19 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 4,032 (derivative) @ $0 | EDGAR |
| 2021-07-01 | 4/A | PLIANT THERAPEUTICS, INC. (PLRX) | Grant/award (A): 13,286 (derivative) @ $0 | EDGAR |
| 2021-06-30 | 4 | PLIANT THERAPEUTICS, INC. (PLRX) | Grant/award (A): 13,286 (derivative) @ $0 | EDGAR |
| 2021-05-27 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 5,120 @ $0 | EDGAR |
| 2021-01-13 | 4 | PLIANT THERAPEUTICS, INC. (PLRX) | Grant/award (A): 26,573 (derivative) @ $0 | EDGAR |
| 2020-09-01 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Purchase (P): 11,900 @ $78.22 · Purchase (P): 900 @ $78.84 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-26 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1051578 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs